BioSpace News Archive

Lombard Medical Announces Shares to Trade on OTCQX

Lombard anticipates that its common shares will trade under its existing ticker symbol EVAR on the OTCQX Market effective as of the market open on November 9, 2017.

October 30, 2017

·

3 min read

Business

Orthofix International Reports Third Quarter 2017 Financial Results

Net sales were $105.2 million, diluted earnings per share from continuing operations was $0.18 and adjusted earnings per share from continuing operations was $0.42.

October 30, 2017

·

18 min read

Business

Medpace Holdings, Inc. Reports Third Quarter 2017 Results

Net service revenue for the three months ended September 30, 2017 was $98.7 million, an increase of 4.1%, compared to $94.8 million for the comparable prior-year period.

October 30, 2017

·

24 min read

Business

Exactech Q3 Revenue $61.4 Million

Diluted earnings per share for the third quarter was $0.20 based on net income of $2.9 million, compared to third quarter 2016 net income of $3.2 million and diluted earnings per share of $0.22.

October 30, 2017

·

6 min read

Business

Kare Schultz to Join Teva as President and Chief Executive Officer on November 1, 2017

Kare has extensive global pharmaceutical experience and a strong track record in corporate turnarounds, as well as in driving growth and leading international expansion.

October 30, 2017

·

8 min read

Drug Development

Enterome’s EB8018, A First-in-Class Drug Candidate Targeting Crohn’s Disease, Successfully Completes Phase I Study in Healthy Volunteers

EB8018 was found to be well tolerated in healthy volunteers across a wide range of doses tested

October 30, 2017

·

4 min read

Merck KGaA Release: New Data Analyses at ECTRIMS Highlight Benefit-Risk Profile of Investigational Cladribine Tablets in Relapsing Multiple Sclerosis

Merck KGaA announced new benefit-risk data for investigational Cladribine Tablets, for the treatment of relapsing multiple sclerosis (MS), at MSParis2017 in Paris, France.

October 30, 2017

·

10 min read

Drug Development

Actuate Therapeutics Receives Rare Pediatric Disease Designation for 9-ING-41 for Treatment of Neuroblastoma

The Rare Pediatric Disease Designation of 9-ING for the treatment of pediatric neuroblastoma comes in addition to Orphan Drug Designations previously granted by the FDA for neuroblastoma, and separately,

October 30, 2017

·

3 min read

Pharnext’s PLEODRUG PXT3003 to Be Featured at the Upcoming Hereditary Neuropathy Foundation (HNF) Annual Patient-Centered Summit

Pharnext will present, in a poster and during an oral session, an update on its ongoing pivotal Phase 3 clinical trial evaluating its lead PLEODRUG PXT3003.

October 30, 2017

·

3 min read

Deals

PDL BioPharma Issues Statement in Response to Neos Therapeutics Rejection of PDL Acquisition Proposal

PDL BioPharma today issued the following statement in response to the Neos Board of Directors’ rejection of PDL’s October 26 proposal to acquire Neos for $10.25 per share in cash.

October 30, 2017

·

2 min read